No significant difference in morbidity, cancer control for men treated post-prostatectomy using Intensity-modulated radiotherapy (IMRT) over conformal radiotherapy (CRT).
Men who reported sleep problems, including difficulty falling asleep and staying asleep, had up to a twofold increased risk for prostate cancer, according to recently published data.
For older men with nonmetastatic prostate cancer, comorbidities increase risk of other-cause death mortality.
Men with prostate cancer who used statin drugs prior to diagnosis had a decreased risk of prostate-cancer-specific mortality.
High fitness has been linked to reductions in risk of developing and dying from lung, colorectal cancer.
A new tool helps identify men who are best suited for active surveillance of prostate cancer, predicting which are more likely to harbor an aggressive form of the disease.
Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men, and they were at a greater risk for subsequently developing prostate cancer, according to a new study.
The FDA has approved Xofigo (radium Ra 223 dichloride; Bayer) for the treatment of symptomatic late-stage castration-resistant prostate cancer with bone metastases.
Significant associations seen in men's urinary and sexual function based on surgeon performing radical prostatectomy.
A new analysis has found that the loss or amplification of particular DNA regions contributes to the development of prostate cancer, and that patients with two of these DNA changes have a high likelihood of dying from the disease.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|